To view other lists in the same category, please VISIT LISTS HOME PAGE or select a list from the above dropdown list of article titles

1. Using the theory of reasoned action to explain physician intention to prescribe emergency contraception.
2. The provision and funding of contraceptive services at publicly funded family planning agencies: 1995-2003.
3. A 'mystery shopper' project to evaluate sexual health and contraceptive services for young people in Croydon.
4. Attitudes and prescribing preferences of health care professionals in the United States regarding use of extended-cycle oral contraceptives.
5. Changes in menstrual pattern and ovarian function following bipolar electrocauterization of the fallopian tubes for voluntary surgical contraception.
6. Combined oral contraceptive use among women with hypertension: a systematic review.
7. Community pharmacy supply of emergency hormonal contraception: a structured literature review of international evidence.
8. Comparison of two regimens of a monthly injectable contraceptive containing dihydroxyprogesterone acetophenide and estradiol enanthate. [Comparación de dos regimenes de un anticonceptivo inyectable mensual que contiene acetofenida de dihidroxiprogesterona y enantato de estradiol.]
9. Contesting contraceptive innovation-reinventing the script.
10. Contraception: an international perspective.
11. Discontinuous low-dose flutamide-metformin plus an oral or a transdermal contraceptive in patients with hyperinsulinaemic hyperandrogenism: normalizing effects on CRP, TNF-alpha and the neutrophil/lymphocyte ratio.
12. Does use of hormonal contraceptives among women with thrombogenic mutations increase their risk of venous thromboembolism? A systematic review.
13. Effect of oral contraceptive pill pretreatment on ongoing pregnancy rates in patients stimulated with GnRH antagonists and recombinant FSH for IVF. A randomized controlled trial.
14. Effective use of hormonal contraceptives Part I: combined oral contraceptive pills.
15. Effective use of hormonal contraceptives Part II: combined hormonal injectables, progestogen-only injectables and contraceptive implants.
16. Effects of a subdermal levonorgestrel contraceptive implant (Norplant) on serum cholesterol, triglycerides, ALT and AST in Iranian women.
17. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the long-term treatment of hirsutism.
18. Hormonal contraceptive use and risk of sexually transmitted infections: a systematic review.
19. Inadvertent vesicular placement of a vaginal contraceptive ring presenting as persistent cystitis.
20. Inadvertent vesicular placement of a vaginal contraceptive ring presenting as persistent cystitis.
21. Medical eligibility criteria for new contraceptive methods: combined hormonal patch, combined hormonal vaginal ring and the etonogestrel implant.
22. A multicentre study investigating subcutaneous etonogestrel implants with injectable testosterone decanoate as a potential long-acting male contraceptive.
23. Ovarian follicular dynamics during conventional vs. continuous oral contraceptive use.
24. Progestogen-only contraceptive use among women with sickle cell anemia: a systematic review.
25. A prospective study of the forearm bone density of users of etonorgestrel- and levonorgestrel-releasing contraceptive implants.
26. Prospective, open-label, noncomparative study to assess cycle control, safety and acceptability of a new oral contraceptive containing gestodene 60 micrograms ethinylestradiol 15 micrograms (Minesse) [Estudio prospectivo no comparativo de diseño abierto para evaluar el control del ciclo, la seguridad y la aceptabilidad de un nuevo anticonceptivo oral con 60 microgramos de gestodeno y 15 microgramos de etinilestradiol (Minesse)]
27. A qualitative study of pharmacists' perspectives on the supply of emergency hormonal contraception via patient group direction in the UK.
28. Reasons for contraceptive nonuse at first sex and unintended pregnancy.
29. Recurrent ascites due to oral contraceptives and pregnancy.
30. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives norgestimate and 35 micrograms of ethinyl estradiol.
31. Safety and efficacy of an extended-regimen oral contraceptive utilizing continuous low-dose ethinyl estradiol.
32. Self-injection of monthly combined hormonal contraceptive.
33. Skin venous thromboembolism by combined oral contraceptive in a woman with acquired angioedema and Factor V Leiden mutation.
34. Treating acne with oral contraceptives: use of lower doses.
35. Unplanned pregnancy: Does past experience influence the use of a contraceptive method?
36. Use of combined oral contraceptives among women with migraine and nonmigrainous headaches: a systematic review.
37. In vitro determination of the contraceptive spermicidal activity of a composite extract of Achyranthes aspera and Stephania hernandifolia.
38. Kazakhstan: Promote LAM for postpartum family planning and birth spacing.
39. Can we improve contraceptive use? [editorial]
40. Contraception and HIV: What do we know and what needs to be done?
41. Focus group research in family planning and reproductive health care.
42. The key lesson of family planning programmes for HIV / AIDS control.
43. Long-acting methods of contraception.
44. Long-acting reversible contraceptives: not only effective, but also a cost-effective option for the National Health Service.
45. Non-contraceptive uses of levonorgestrel-releasing hormone system (LNG-IUS)-a systematic enquiry and overview.
46. Nurse prescribing in family planning.
47. Should coagulation tests be used to determine which oral contraceptive users have an increased risk of thrombophlebitis?
48. Weight gain in obese and nonobese adolescent girls initiating depot medroxyprogesterone, oral contraceptive pills, or no hormonal contraceptive method.
49. The World Health Organization's global guidance for family planning: an achievement to celebrate [editorial]
50. Parent-child relations among minor females attending U.S. family planning clinics.
51. Consistency of condom use among low-income hormonal contraceptive users.
52. Counseling contraception for Malian migrants in Paris: global, state, and personal politics. [Un counseling sur la contraception à l'attention des immigrés maliens à Paris : des politiques internationales, nationales et personnelles.]
53. 'We want someone with a face of welcome': Ugandan adolescents articulate their family planning needs and priorities.
54. A 1-year randomized study to evaluate the effects of a dose reduction in oral contraceptives on lipids and carbohydrate metabolism: 20 micrograms ethinyl estradiol combined with 100 micrograms levonorgestrel.
55. A 1-year study to compare the hemostatic effects of oral contraceptive containing 20 micrograms of ethinylestradiol and 100 micrograms of levonorgestrel with 30 micrograms of ethinylestradiol and 100 micrograms of levonorgestrel.
56. Adolescents demanding a good contraceptive: a study with standardized patients in general practices.
57. Adolescents' reports of parental knowledge of adolescents' use of sexual health services and their reactions to mandated parental notification for prescription contraception.
58. Advanced provision of emergency contraception to postnatal women in China makes no difference in abortion rates: a randomized controlled trial.
59. African American women and family planning services: perceptions of discrimination.
60. Analysing the relationship between family planning workers' contact and contraceptive switching in rural Bangladesh using multilevel modelling.
61. The analysis of qualitative research data in family planning and reproductive health care.
62. Anastrazole and oral contraceptives: a novel treatment for endometriosis.
63. Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer.
64. Angiogenic effects of Norplant contraception on endometrial histology and uterine bleeding.
65. Are affluent, well-educated, career-orientated women knowledgeable users of the oral contraceptive pill?
66. Are women ready for more liberal delivery of emergency contraceptive pills?
67. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis.
68. Attitudes towards family planning in the Southeast Anatolian Project (SEAP) region of turkey.
69. Availability of services for emergency contraceptive pills at high school-based health centers.
70. Awareness of emergency contraception.
71. Beyond the pill: new data and options in hormonal and intrauterine contraception.
72. Bioavailability of the Yuzpe and levonorgestrel regimens of emergency contraception: vaginal vs. oral administration.
73. Birth intervals and injectable contraception in sub-Saharan Africa.
74. Bleeding patterns after immediate initiation of an oral compared with a vaginal hormonal contraceptive.
75. Body mass index, weight, and oral contraceptive failure risk.
76. Bone mineral density in women aged 40-49 years using depot-medroxyprogesterone acetate, norethisterone enanthate or combined oral contraceptives for contraception.
77. Cervical cancer screening continues to limit provision of contraception.
78. Child schooling and contraceptive use in rural Africa: A Ghanaian case study.
79. Clinical experience and acceptability of the etonogestrel subdermal contraceptive implant. [Experiencia clínica y aceptabilidad del implante anticonceptivo subdérmico de etonogestrel.]
80. Clinical performance and menstrual bleeding patterns with three dosage combinations of a Nestorone progestogen/ethinyl estradiol contraceptive vaginal ring used on a bleeding-signaled regimen.
81. The combined contraceptive vaginal ring (NuvaRing) and endometrial histology.
82. The combined contraceptive vaginal ring and bone mineral density in healthy pre-menopausal women. [Anillo anticonceptivo vaginal combinado y densidad mineral ósea en mujeres premenopáusicas sanas.]
83. Combined oral contraceptives in women with systemic lupus erythematosus.
84. Community-based distribution and contraception usuage in Iran.
85. Comparative acceptability of combined and progestin-only injectable contraceptives in Kenya.
86. A comparative study of clinical management strategies for vaginal discharge in family planning and genitourinary medicine settings.
87. A comparative study of monophasic oral contraceptives containing either drospirenone 3 micrograms or levonorgestrel 150 micrograms on premenstrual symptoms.
88. Comparison of ethinylestradiol pharmacokinetics in three hormonal contraceptive formulations: the vaginal ring, the transdermal pathch and an oral contraceptive.
89. Comparison of the metabolic effect of oral contraceptive and nonhormonal contraceptive use in women over 40 years old.
90. Comparison of vaginal and oral administration of emergency contraception.
91. Consultations concerning contraception and induced abortions among university students -- trends in Finland 1986-2003.
92. Contraception or abortion? Inaccurate descriptions of emergency contraception in newspaper articles, 1992-2002.
93. Contraceptive vaginal rings releasing Nestorone and ethinylestradiol: a 1-year dose-finding trial.
94. Cost-effectiveness and contraceptive effectiveness of the transdermal contraceptive patch.
95. Cultivating men's interest in family planning in rural El Salvador. [Incentivación del interés de los hombres en la planificación familiar en comunidades rurales de El Salvador.]
96. Depo-Provera: use of a long-acting progestin injectable contraceptive in Turkish women.
97. Determinants of spacing contraceptive use among couples in Mumbai: a male perspective.
98. Different oral contraceptives and voice quality -- an observational study.
99. The dilemma of past success: insiders' views on the future of the international family planning movement.
100. Direct access to emergency contraception through pharmacies and effect on unintended pregnancy and STIs. A randomized controlled trial.
101. Diversity in family planning use among ethnic groups in Guatemala. [Diversidad en el uso de la planificación familiar en grupos étnicos de Guatemala.]
102. Does dedicated pre-abortion contraception counselling help to improve post-abortion contraception uptake?
103. Double-blinded randomized controlled trial of estrogen supplementation in adolescent girls who receive depot medroxyprogesterone acetate for contraception.
104. Ease of insertion, contraceptive efficacy and safety of new T-shaped levonorgestrel-releasing intrauterine systems.
105. The effect of hormonal contraception on the adequacy of colposcopic examination of the cervix.
106. The effect of increased access to emergency contraception among young adolescents.
107. Effect of Norplant contraceptive on the bones of Nigerian women as assessed by quantitative ultrasound and serum markers of bone turnover.
108. Effect of oral contraceptive treatment on bone mass acquisition in skeletally immature young female rats.
109. Effects of an oral contraceptive (norgestimate/ethinyl estradiol) on bone mineral density in women with hypothalamic amenorrhea and osteopenia: an open-label extension of a double-blind, placebo-controlled study.
110. Effects of an oral contraceptive containing drospirenone on bone turnover and bone mineral density.
111. Effects of making emergency contraception available without a physician's prescription: a population-based study.
112. Effects of two combined oral contraceptives containing ethinyl estradiol 20 micrograms combined with either drospirenone or desogestrel on lipids, hemostatic parameters and carbohydrate metabolism.
113. Efficacy and safety of a contraceptive vaginal ring (NuvaRing) compared with a combined oral contraceptive: a 1-year randomized trial. [Ensayo aleatorizado a un año para determinar la eficacia y seguridad de un anillo anticonceptivo vaginal (NuvaRing) en comparación con un anticonceptivo oral combinado.]
114. Embodied expertise: women's perceptions of the contraception consultation.
115. Emergency contraception and prevention of induced abortion in India.
116. Emergency contraception knowledge among women in a Boston community.
117. Emergency contraception moves behind the counter [editorial]
118. Emergency contraception: an intervention on primary care providers.
119. Emergency contraceptive pills: dispensing practices, knowledge and attitudes of South Dakota pharmacists.
120. Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimen.
121. Estradiol supplementation modulates neuroendocrine response to M-hlorophenylpiperazine in menstrual status migrainosus triggered by oral contraception-free interval.
122. Evaluation of fusogenic trophoblast surface epitopes as targets for immune contraception.
123. Evaluation of lipid profile in adolescents during long-term use of combined oral hormonal contraceptives. [Evaluación del perfil lipídico en adolescentes durante el uso a largo plazo de anticonceptivos hormonales orales.]
124. Expanding family planning options: offering the Standard Days Method to women in Istanbul.
125. Exploring older adolescents' and young adults' attitudes regarding male hormonal contraception: applications for clinical practice.
126. Factors influencing young women's decision making regarding hormonal contraceptives: a qualitative study.
127. Failure of the emergency contraceptive levonorgestrel and the risk of adverse effects in pregnancy and on fetal development: an observational cohort study.
128. Field experiences integrating family planning into programs to prevent mother-to-child transmission of HIV. [Experiencias de campo: integración de la planificación familiar en programas de prevención de la transmisión madre-hijo del VIH.]
129. Gonorrhea and chlamydia infection among women visiting family planning clinics: racial variation in prevalence and predictors.
130. HIV testing and counseling among adolescents attending family planning clinics.
131. Hormonal contraception and physiology: a research-based theory of discontinuation due to side effects. [Anticoncepción hormonal y fisiología: teoría de la interrupción debido a los efectos secundarios basada en la investigación.]
132. Hormonal contraceptive use and the effectiveness of highly active antiretroviral therapy.
133. Identification of novel endometrial targets for contraception.
134. The impact of franchised family planning clinics in poor urban areas of Pakistan.
135. Impact on contraceptive practice of making emergency hormonal contraception available over the counter in Great Britain: repeated cross sectional surveys.
136. Increased contraceptive use one year post-abortion.
137. Increasing contraceptive use in rural Pakistan: an evaluation of the Lady Health Worker Programme.
138. Increasing male involvement in family planning decision making: trial of a social-cognitive intervention in rural Vietnam.
139. Initial Asian experience in hysteroscopic sterilisation using the Essure permanent birth control device.
140. Interaction of St. John's Wort with oral contraceptives: effects on the pharmacokinetics of norethindrone and ethinyl estradiol, ovarian activity and breakthrough bleeding.
141. Is genitourinary medicine meeting the contraception needs of clinic attendees?
142. Late follicular phase administration of levonorgestrel as an emergency contraceptive changes the secretory pattern of glycodelin in serum and endometrium during the luteal phase of the menstrual cycle. [La administración folicular de fase tardía de levonorgestrel como anticonceptivo de emergencia cambia el patrón secretorio de la glicodelina sérica y el endometrio durante la fase luteínica del ciclo menstrual.]
143. Long-term use of oral contraceptives increases the risk of miscarriage.
144. Maintenance of ovulation inhibition with the 75-micrograms desogestrel-only contraceptive pill (Cerazette) after scheduled 12-h delays in tablet intake.
145. Male participation in family planning: results from a qualitative study in MPIGI District, Uganda.
146. Maternal and child health and family planning service utilization in Guatemala: implications for service integration. [Utilización de los servicios de salud maternoinfantil y planificación familiar en Guatemala: consecuencias de la integración de los servicios.]
147. Measured and reported weight change for women using a vaginal contraceptive ring vs. a low-dose oral contraceptive.
148. Migration and the diffusion of modern contraceptive knowledge and use in rural Guatemala. [Migración y difusión del conocimiento y el uso de anticonceptivos modernos en comunidades rurales de Guatemala.]
149. The morning after on the internet: usage of and questions to the emergency contraception website.
150. A multicenter phase IIb study of a novel combination of intramuscular androgen (testosterone decanoate) and oral progestogen (etonogestrel) for male hormonal contraception.
151. A new method for estimating the effectiveness of emergency contraception that accounts for variation in timing of ovulation and previous cycle length.
152. Novel antiangiogenic agents for use in contraception.
153. Oral contraceptives for dysmenorrhea in adolescent girls. A randomized trial.
154. Oral contraceptives improve endothelial function in amenorrheic athletes.
155. Postpartum contraception: the New Mexico Pregnancy Risk Assessment Monitoring System.
156. Potential impact of oral contraceptive choice on myocardial infarction mortality and deep vein thrombosis.
157. Predictors of contraception knowledge and use among postpartum adolescents in El Salvador. [Predictores de conocimiento y uso de anticonceptivos en puérperas adolescentes en El Salvador.]
158. Primary care services for an emergency department population: a novel location for contraception.
159. A prospective study of immediate initiation of depo medroxyprogesterone acetate contraceptive injection.
160. Prospective study on sexual behavior of women using 30 micrograms ethinylestradiol and 3 micrograms drospirenone oral contraceptive.
161. Provision of emergency hormonal contraception through community pharmacies in a rural area.
162. A qualitative study of women's use of emergency contraception.
163. A randomized prospective trial comparing gonadotropin-releasing hormone (GnRH) antagonist/recombinant follicle-stimulating hormone (rFSH) versus GnRH-agonist/rFSH in women pretreated with oral contraceptives before in vitro fertilization.
164. A randomized trial of clinican-delivered interventions promoting barrier contraception for sexually transmitted disease prevention.
165. The remaining barriers to the use of emergency contraception: perception of pregnancy risk by women undergoing induced abortions.
166. Reproductive health, the Arab world and the internet: usage patterns of an Arabic-language emergency contraception web site.
167. Ruling out pregnancy among family planning clients: the impact of a checklist in three countries.
168. Safety and efficacy of Implanon, a single-rod implantable contraceptive containing etonogestrel.
169. Same-day initiation of the transdermal hormonal delivery system (contraceptive patch) versus traditional initiation methods.
170. Scaling up postabortion contraceptive service -- results from a study conducted among women having unwanted pregnancies in urban and rural Tanzania.
171. A scanning electron microscopic study of the contraceptive vaginal ring.
172. The selection of family planning discussion partners in Nepal.
173. Serum and peritoneal fluid levels of levonorgestrel in women with endometriosis who were treated with an intrauterine contraceptive device containing levonorgestrel.
174. Serum Nestorone and ethinyl estradiol levels, and ovulation inhibition in women using three different dosage combinations of a Nestorone progestogen-ethinyl estradiol contraceptive vaginal ring on a bleeding-signaled regimen.
175. Sexual activity, fertility and contraceptive use in middle-aged and older men: men in Australia, Telephone Survey (MATeS)
176. Short-term oral contraceptive use and the risk of epithelial ovarian cancer.
177. Steroid hormones for contraception in men: systematic review of randomized controlled trials.
178. Steroid receptor expression in vaginal epithelium of healthy fertile women and influences of hormonal contraceptive usage.
179. Superior cycle control with a contraceptive vaginal ring compared with an oral contraceptive containing 30 micrograms ethinylestradiol and 150 micrograms levonorgestrel: a randomized trial.
180. Suppression of estrogen-withdrawal headache with extended transdermal contraception.
181. TCu 380A IUD: a reversible permanent contraceptive method in women over 35 years of age. [DIU TCu 380A: método anticonceptivo permanente reversible en mujeres de más de 35 años.]
182. Teen contraceptive decisions: childbearing intentions are the tip of the iceberg.
183. Treatment of premenstrual dysphoric disorder with a new drospirenone-containing oral contraceptive formulation.
184. A trial of contraceptive methods in women with systemic lupus erythematosus.
185. Twenty micrograms vs. >20 micrograms oral contraceptives for contraception: systematic review of randomized controlled trials.
186. Unsafe abortion in Tanzania and the need for involving men in postabortion contraceptive counseling.
187. Use of exogenous hormones by women and colorectal cancer: evidence from the Royal College of General Practitioners' Oral Contraception Study.
188. The use of triphasic oral contraceptives in a continuous use regimen.
189. Vaginal contraceptive activity of a chelated vanadocene.
190. Valuable safeguard or unnecessary burden? Characterization of physician consultations for oral contraceptive use in Mexico City. [¿Protección valiosa o carga innecesaria? Descripción de las consultas médicas por uso de anticonceptivos orales en Ciudad de México.]
191. The in vitro effect of emergency contraception doses of levonorgestrel on the acrosome reaction of human spermatozoa. [Efecto in vitro de dosis de levonorgestrel como anticonceptivos de emergencia en la reacción acrosómica de los espermatozoides humanos.]
192. What happened when Scottish women were given advance supplies of emergency contraception? A survey and qualitative study of women's views and experiences.
193. When family planning services fail: experience from Bangladesh.
194. Workforce specialty review for family planning and reproductive health care 2003 / 2004: England, Wales, Northern Ireland and Scotland.
195. SWS 4th Quarter 2004 Survey Report on Family Planning for the Department of Health (DOH)
196. The future of the international family planning movement.
197. Sperm with bent tails point to possible male contraceptive.
198. Emergency contraception's mode of action clarified.
199. The effect of community nurses and health volunteers on child mortality: the Navrongo Community Health and Family Planning Project.
200. Addressing the family planning needs of HIV-positive PMTCT clients: baseline findings from an operations research study.
201. Fertility and contraception among HIV-positive women.
202. Community-based family planning in Kenya: meeting new challenges.
203. Contraceptives -- both needed and scorned.
204. Recent trends in abortion and contraception in 12 countries.
205. Hormonal contraception and HIV: more research needed; no changes in family planning practices currently warranted.
206. Postabortion family planning benefits clients and providers.
207. Family planning success stories in sub-Saharan Africa.
208. Family planning for postpartum women: seizing a missed opportunity.
209. Priorities for family planning and HIV / AIDS integration.
210. Client-provider interaction: key to successful family planning.
211. LAM users. Transition to other modern methods of contraception after six months postpartum.
212. Keeping up with evidence. A new system for WHO's evidence-based family planning guidance.
213. New contraceptive choices. / Nuevas opciones de anticonceptivos. / Nouveaux choix contraceptifs.
214. Integrating family planning into VCT services. Guest editorial. [L'intégration du planning familial à des services de CVD. Éditorial invité.]
215. Beyond the issue of pharmacist refusals: pharmacies that won't sell emergency contraception.
216. Women's exposure to mass media and use of family planning methods: A case study of Goa.
217. Contraceptive use in women from a resettlement area in Delhi.
218. Providing basic genetic services: What role for family planning clinics?
219. Legislatures in three states seek to expand medicaid family planning services eligibility.
220. Condoms, contraceptives and nonoxynol-9: complex issues obscured by ideology.
221. Use of family planning services in the transition to a static clinic system in Bangladesh: 1998-2002.
222. Oral contraceptive use and female genital arousal: methodological considerations.
223. Reliability of self-reported contraceptive use and sexual behaviors among adolescent girls.
224. Preventing mother-to-child transmission of HIV: a practical guide for providing HIV-positive women with family planning services. 2nd ed.
225. Trends in demographic, family planning and health indicators in Ghana, 1960-2003. Trend analysis of Demographic and Health Surveys data.
226. Contraception perspective in Pakistan [editorial]
227. Family planning practices among currently married women in Khairpur district, Sindh, Pakistan.
228. Draw the circle wide to add contraceptive ring.
229. Update:Today contraceptive sponge returns to U.S. drugstore shelves.
230. Funding cuts threaten family planning source.
231. Emergency contraception [letter]
232. Emergency contraception [letter]
233. Emergency contraception [letter]
234. Do Indonesian medical practitioners approve the availability of emergency contraception over-the-counter? A survey of general practitioners and obstetricians in Jakarta.
235. Hearing native voices: contraceptive use in Matemwe Village, East Africa.
236. Contraceptive implants.
237. Contraceptive practices and awareness of emergency contraception in educated working women.
238. Recommendations to strengthen the role of Lady Health Workers in the National Program for Family Planning and Primary Health Care in Pakistan: the health workers perspective.
239. What you need to know. The difference between medical abortion and emergency contraceptive pills.
240. What you need to know. The facts about emergency contraception.
241. Contraceptive services.
242. Contraceptive use.
243. Critical role of Medicaid in financing family planning services -- state-level data [memorandum]
244. Emergency contraception. State policies in brief as of August 16, 2005.
245. Family planning annual report: 2004 summary. Part 1.
246. Insurance coverage of contraceptives. State policies in brief as of August 1, 2005.
247. Medicaid: a critical source of support for family planning in the United States.
248. Minors' access to contraceptive services. State policies in brief as of August 1, 2005.
249. Public funding for contraceptive, sterilization and abortion services, FY 1980-2001. National and state tables and figures.
250. Zambia case study: Ready for Change. A repositioning family planning case study.
251. Malawi case study: Choice, Not Chance. A repositioning family planning case study.
252. Ghana case study: `Give them the power'. A repositioning family planning case study.
253. Moving family planning programs forward: learning from success in Zambia, Malawi, and Ghana. The Repositioning Family Planning Case Study synthesis report.
254. Improving the use of long-term and permanent methods of contraception in Guinea: a performance needs assessment.
255. Repositioning family planning conferences: a "how to" hand book.
256. Ensuring contraceptive security for HIV-positive women.
257. Improving access to long-term contraceptives in rural Guatemala through the Ministry of Health. [Mejoramiento del acceso a anticonceptivos a largo plazo en las zonas rurales de Guatemala a través del Ministerio de la Salud.]
258. Improving the Health Status of Malagasy through Social Marketing of Hormonal Contraceptives to Improve Reproductive Health and Maternal and Child Health products to reduce Morbidity and Mortality from Malaria and Diarrheal Disease. Final report, June 1, 2004 - August 31, 2005.
259. Child Survival 20 - Mali: Partnership to Maximize Access and Quality of Family Planning Services in Ségou, Mali. First annual report. Cooperative Agreement No. GHA-A-00-04-00003, 30 September 2004 - 30 September 2009.
260. Democratic Republic of Congo Program: Rapid Contraceptive Increase in a Post-Conflict Setting. Integrating services through local partners, 2003-2005. End of project report.
261. Save the Children. USA. Expanding Family Planning and Reproductive Health Services in Liben district, Guji zone, Oromia region, Ethiopia. Ethiopia Flex Fund Sub-award ACQ-503-00. October 1st 2003 to September 30th, 2007. Second annual report. Reporting period: October 1st 2004 to September 30th, 2005.
262. Strengthening Social Acceptance of Family Planning in the Philippines: a communication and advocacy project, USAID Contract No. 492-C-00-02-00019-00. Annual report (Year 3): October 1, 2004 to August 14, 2005.
263. Senegal Maternal Health / Family Planning Project: final report. [Projet " Santé maternelle / Planning familial " au Sénégal : Rapport final.]
264. Population assistance and family planning programs: issues for Congress. Updated May 26, 2005. [Programas de asistencia a la población y de planificación familiar: temas para el Congreso. Actualización al 26 de mayo de 2005.]
265. KAP on emergency contraception among medical and general community of Bhopal city.
266. Change in bone mineral density among adolescent women using and discontinuing depot medroxyprogesterone acetate contraception.
267. Absence of pharmacokinetic interactions of the combined contraceptive vaginal ring NuvaRing with oral amoxicillin or doxycycline in two randomised trials.
268. Adolescent use of the monthly contraceptive injection.
269. Adolescents' experience with the combined estrogen and progestin transdermal contraceptive method Ortho Evra.
270. Advance supply of emergency contraception: a randomized trial in adolescent mothers.
271. AF-2364 [1-(2,4-dichlorobenzyl)-1H-indazole-3-carbohydrazide] is a potential male contraceptive: a review of recent data.
272. Another FDA expert resigns over emergency contraception delay.
273. Antimicrobial peptides as microbicidal contraceptives: prophecies for prophylactics - a mini review.
274. Antiprogestins for contraception?
275. Assessment of contraceptive services in a maternity unit of a district general hospital in the UK.
276. The association of Candida infection with intrauterine contraceptive device.
277. Attitudes and practices of private medical providers towards family planning and abortion services in Nigeria.
278. Availability of emergency contraception: a survey of hospital emergency department staff.
279. Awareness, knowledge and perceptions of emergency contraception among health care providers in and around Mumbai.
280. Biological activity assessment of a novel contraceptive antimicrobial agent.
281. The biological role of smoking, oral contraceptive use and endogenous sexual steroid hormones in invasive squamous epithelial cervical cancer.
282. Blood pressure, smoking and oral contraceptive control after cryptogenic stroke in young adults in the PFO-ASA study.
283. Body weight and contraceptives. Exploring the relationship and dosage risks.
284. BRCA1 and BRCA2 germ-line mutations and oral contraceptives: to use or not to use.
285. Bulletin: FDA issues approvable status for single-rod contraceptive implant.
286. Change in contraceptive choices and the effect of education on use of contraception at the family planning clinic Sisli Etfal Training and Research Hospital, Istanbul, Turkey.
287. Changes in young women's awareness, attitudes, and perceived barriers to using emergency contraception.
288. Client participation and provider communication in family planning counselling and the sample study from Turkey.
289. Clinical trials begin for spray-on contraceptive.
290. Clinical, ethical, and medical legal considerations on emergency contraception.
291. The combined contraceptive vaginal device (NuvaRing): A comprehensive review.
292. Communication, ideation and contraceptive use in Burkina Faso: an application of the propensity score matching method. [Communication, idéation et utilisation des contraceptifs au Burkina Faso : application de la méthode d'appariement par score de propension.]
293. Concerns regarding design, analysis, and interpretation of the Morrison Study on Hormonal Contraceptive Use and Acquisition of Cervical Infections [letter]
294. Concerns regarding design, analysis, and interpretation of the Morrison study on hormonal contraceptive use and acquisition of cervical infections [letter] [reply]
295. Conference on Repositioning Family Planning in West Africa: Rapporteur-General's report.
296. Conservatives' agenda threatens public funding for family planning.
297. Conspiracy beliefs about birth control: barriers to pregnancy prevention among African Americans of reproductive age.
298. Contraception during perimenopause.
299. Contraception for college students.
300. Contraception in diabetic women: an Italian study.
301. Contraception in teens with medical problems.
302. Contraception usage over the age of 40 in Polish female population aged 45 - 54.
303. Contraception within six-month postpartum in rural Vietnam: Implications on family planning and maternity services.
304. Contraception's proved potential to fight HIV [letter]
305. Contraceptive coverage grows, but significant challenges remain.
306. Contraceptive efficacy, compliance and beyond: factors related to satisfaction with once-weekly transdermal compared with oral contraception.
307. Contraceptive equity and access in the United States: a 2005 update [editorial]
308. Contraceptive prevalence among young women in Nigeria.
309. Contraceptive use among the poor in Indonesia.
310. Contraceptive use by diabetic and obese women.
311. Contraceptive vaccines targeting sperm.
312. Contraceptive vaccines.
313. Control of spermatogenesis in primate and prospect of male contraception.
314. Cost savings from use of emergency contraceptive pills in Australia.
315. Creating conditions for greater private sector participation in achieving contraceptive security.
316. Creating options in family planning for the private sector in Latin America. [Nuevas opciones de planificación familiar para el sector privado en América Latina.]
317. Critical issues in contraceptive and STI acceptability research.
318. The debate about over-the-counter emergency contraceptive pills.
319. Decisions denied: women's access to contraceptives and abortion in Argentina. [Decisiones denegadas: acceso de las mujeres a los métodos anticonceptivos y al aborto en Argentina.]
320. Delivery options for contraceptives.
321. Demographic analysis of post-abortive and interval-administered hormonal contraceptive methods.
322. Depression among female family planning patients: prevalence, risk factors, and use of mental health services.
323. Description of emergency contraception in the media [letter]
324. The determinants of fertility in rural Peru: program effects in the early years of the national family planning program. [Factores determinantes de fertilidad en áreas rurales de Perú: efectos del Programa Nacional de Planificación Familiar durante sus primeros años de aplicación.]
325. Direct access to emergency contraception [letter]
326. Direct access to emergency contraception [letter]
327. Direct access to emergency contraception. In reply [letter]
328. Do depot medroxyprogesterone acetate contraceptive injections cause mood changes and memory impairment?
329. Does contraception affect HIV treatment?
330. Does oral contraceptive use affect maximum force production in women?
331. Doorstep delivery increases adoption of contraceptives in rural areas of Pakistan.
332. Ectopic pregnancy with postcoital contraception - a case report.
333. Effect of temporary out-migration of husbands on use of contraception in a rural area of Bangladesh.
334. Effects of local estrogen therapy on recurrent urinary tract infections in young females under oral contraceptives.
335. Effects of low dose oral contraceptives on serum total cholesterol, TAG, HDL-C and LDL-C levels in contraceptive users.
336. Effects of prolonged use of injectable hormonal contraceptive on serum lipid profile.
337. Emergency contraception [letter]
338. Emergency contraception -- a different interpretation [letter]
339. Emergency contraception for women aged over 40 years [letter]
340. Emergency contraception for women aged over 40 years [letter] [reply]
341. Emergency contraception use by Irish teenagers.
342. Emergency contraception. Nurses can empower women.
343. Emergency contraception: prudes and prejudice [editorial]
344. Emergency contraception: the politics of post-coital contraception.
345. Enhanced access to emergency contraception.
346. Ethinyl estradiol / levonorgestrel (Seasonale) for oral contraception.
347. The expanding role of genetics in contraception and women's health [editorial]
348. Extended cycle hormonal contraception in adolescents.
349. Extended use of the oral contraceptive pill -- is it an acceptable option for the adolescent?
350. Family planning clinics may not be the best option for serving Pakistan's poor.
351. Family planning for obese women: challenges and opportunities [editorial]
352. Fatty acid reesterification but not oxidation is increased by oral contraceptive use in women.
353. FDA criticised for rejecting over the counter emergency contraception.
354. FFPRHC Guidance (July 2005): The use of contraception outside the terms of the product licence.
355. Folic acid fortification: Should oral contraceptives be next? Con.
356. Folic acid fortification: Should oral contraceptives be next? Pro.
357. Frameless versus classical intrauterine device for contraception.
358. From family planning to sexual and reproductive health: policy implications.
359. Gene knockouts that cause female infertility: search for novel contraceptive targets.
360. Headache and combination estrogen-progestin oral contraceptives: integrating evidence, guidelines, and clinical practice.
361. Hopes for male contraception.
362. Hormonal Contraception and HIV: Science and Policy. Africa Regional Meeting, Nairobi 19-21 September 2005. Statement (final)
363. Hormonal contraception in men.
364. Hormonal contraceptives and weight gain.
365. Hormonal-based male contraceptive moves ahead.
366. The impact of menstrual side effects on contraceptive discontinuation: findings from a longitudinal study in Cairo, Egypt.
367. Improving contraceptive technology: is it a zero-sum game? [editorial]
368. The influence of long-term hormonal contraception and smoking on plasma concentrations of nitrites and nitrates.
369. Integrating family planning and prevention of mother-to-child HIV transmission in resource-limited settings.
370. Integration of HIV / AIDS and family planning [letter]
371. Integration of HIV / AIDS and family planning [letter] [reply]
372. Iranian women's perceptions of family-planning services quality: a client-satisfaction survey.
373. Is family planning a subspecialty of obstetrics and gynecology? [editorial]
374. Ischemic colitis associated with naratriptan and oral contraceptive use.
375. It takes two: men and contraception.
376. Jordanian married Muslim women's intentions to use oral contraceptives.
377. Justice department fails to mention emergency contraception after rape.
378. Knowledge and attitude of males regarding birth spacing and contraception.
379. Knowledge, attitudes and practices regarding emergency contraception among family-planning providers in Turkey.
380. Long-acting methods of contraception.
381. Male contraceptives are gaining momentum.
382. The MDGs: condoms as disease prevention, not just contraception [editorial]
383. Menstrual and contraceptive issues among young women with developmental delay: a retrospective review of cases at the hospital for sick children, Toronto.
384. Missed contraceptive pill recommendations [letter]
385. Missed contraceptive pills and the critical pill-free interval.
386. Model-based clustering of sequential data with an application to contraceptive use dynamics. [Agrupamiento basado en un modelo de secuencias de datos con una aplicación a la dinámica del uso de anticonceptivos.]
387. Mortality from venous thromboembolism in young Swedish women and its relation to pregnancy and use of oral contraceptives -- an approach to specifying rates.
388. Mullerian adenosarcoma of the uterus associated with long-term oral contraceptive use [letter]
389. Myths regarding contraception in southwest Nigeria [letter]
390. New Low- and High-Tech Calendar Methods of Family Planning [by] Ferhing, R. J. (2005). Journal of Midwifery and Women's Health, 50(1), 31-38. Comment.
391. New low- and high-tech calendar methods of family planning.
392. New research highlights infertility, improvements in Ghana's family planning services, and female genital cutting.
393. No bones about it - depot medroxyprogesterone acetate remains an excellent contraceptive option for adolescents.
394. No political will to seek innovative contraception [letter]
395. No political will to seek innovative contraception. Focus instead on other reproductive issues, which may make birth-control superfluous [letter]
396. Nonprescription status for emergency contraception.
397. Ominous convergence: sex trafficking, prostitution and international family planning.
398. Oral contraception: five important issues.
399. Oral contraceptive use and risk of early-onset breast cancer in carriers and noncarriers of BRCA1 and BRCA2 mutations.
400. Oral contraceptive use, reproductive factors, and colorectal cancer risk: findings from Wisconsin.
401. Oral contraceptives and the management of hyperandrogenism-polycystic ovary syndrome in adolescents.
402. Oral contraceptives in systemic lupus erythematosus - a tough pill to swallow? [editorial]
403. Oral contraceptives use and weight gain in women with a Central European life-style.
404. ORG 33628 and ORG 31710 to control vaginal bleeding in progestin-only contraceptive regimens.
405. Ovarian actinomycosis in absence of intrauterine contraceptive device: an unusual presentation.
406. Over-the-counter availability of Plan B emergency contraception: further discussion and commentary [editorial]
407. Parental consent for minors to receive contraceptives [letter]
408. Parental involvement and young women's contraceptive use.
409. Parental notification laws for minors' access to contraception: what do parents say?
410. Parents and partners: enhancing participation in contraception use.
411. Pharmacists' knowledge and perceptions of emergency contraceptive pills in Soweto and the Johannesburg Central Business District, South Africa.
412. Pilot studies in family planning and reproductive health care.
413. Placing emergency contraception in the hands of women [editorial]
414. The potential of mifepristone (RU-486) as an emergency contraceptive drug.
415. A potential role of odorant receptor agonists and antagonists in the treatment of infertility and contraception.
416. Prebirth psychosocial factors as predictors of consistency in contraceptive use among Taiwanese adolescent mothers at 6 months postpartum.
417. Predictors of men's acceptance of modern contraceptive practice: study in rural Vietnam.
418. Preface: male infertility, from contraception to therapy [editorial]
419. Pregnancy and oral contraceptives in factor V deficiency: a study of 22 patients (five homozygotes and 17 heterozygotes) and review of the literature.
420. Previous oral contraceptive use and breast cancer risk according to hormone replacement therapy use among postmenopausal women.
421. Professional competence and contraceptive care. [Competencia profesional y atención anticonceptiva.]
422. Prolonged use of Norplant contraceptive subdermal implants.
423. Promoting informed choice: evaluating a decision-making tool for family planning clients and providers in Mexico.
424. Promoting the safety and use of hormonal contraceptives.
425. Providers' knowledge of, attitude to and practice of emergency contraception.
426. Rationale for decreasing the number of days of the hormone-free interval with use of low-dose oral contraceptive formulations.
427. Reanalysis of the women's health initiative oral contraceptive data reveals no evidence of delayed cardiovascular benefit.
428. Reasons for requesting emergency contraception: a survey of 506 Italian women.
429. The relationship between males' attitudes to partner violence and use of contraceptive methods in Turkey.
430. Reproductive health, contraception and fertility behaviour among slum dwellers in Andhra Pradesh.
431. The role of body weight in oral contraceptive failure: results from the 1995 National Survey of Family Growth.
432. Role of progestins in contraception.
433. Safe and effective use of contraceptives.
434. A selective androgen receptor modulator for hormonal male contraception.
435. Selective exposure reporting and Medline indexing limited the search sensitivity for observational studies of the adverse effects of oral contraceptives.
436. Sexual behaviour and contraceptive practice of future doctors in southwest Nigeria.
437. Sexual health, contraception, and teenage pregnancy.
438. Single dose of 1.5 mg levonorgestrel for emergency contraception.
439. The social construction of 'reproductive vulnerability' in family planning clinics.
440. Some recommendations for the use of emergency contraception.
441. Some recommendations for the use of oral contraceptives.
442. State policies in brief as of August 1, 2005. State family planning funding restrictions.
443. State policies in brief as of August 1, 2005. State Medicaid family planning eligibility expansions.
444. Stopping oral contraceptives: an effective blood pressure-lowering intervention in women with hypertension. [Interrupción del consumo de anticonceptivos orales: una intervención eficaz para reducir la tensión arterial en mujeres hipertensas.]
445. Swedish teenager perceptions of teenage pregnancy, abortion, sexual behaivor, and contraceptive habits - a focus group study among 17-year-old female high-school students.
446. Talking about sex: religion and patterns of parent-child communication about sex and contraception.
447. Teenage contraceptive use in Iceland: a gender perspective.
448. Teenagers' sexual behavior might become more risky if parents had to know of family planning clinic visits.
449. Teens improve contraceptive use, but more women at risk for pregnancy.
450. Threats to family planning services in Michigan: organizational responses to economic and political challenges.
451. Title X family planning annual report. Forms and instructions.
452. In training. What's new in adolescent contraception: what residents and teachers need to know.
453. Transvaginal contraception -- avoid the bladder.
454. Understandings of the 'natural' body: a comparison of the views of users and providers of emergency contraception.
455. Unexpectedly high prevalence of sexually transmitted diseases in married women attending family planning clinics in Yaounde, Cameroon [letter] [Taux étonnamment élevé de prévalence des maladies transmises sexuellement chez les femmes mariées fréquentant les cliniques de planification familiale à Yaoundé au Cameroun] [lettre.]
456. US pharmacies vow to withhold emergency contraception.
457. Use of various contraceptive methods and time of conception in a community-based population.
458. Violence against women: an examination of men's attitudes and perceptions about wife beating and contraceptive use.
459. Who is eligible to use the different types of contraceptives?
460. Why do women miss oral contraceptive pills? An analysis of women's self-described reasons for missed pills.
461. Women and postfertilization effects of birth control: consistency of beliefs, intentions and reported use.
462. Women on top: the relative influence of wives and husbands on contraceptive use in KwaZulu-Natal.
463. Women's autonomy, education and contraception use in Pakistan: a national study.
464. U.S. insurance coverage of contraceptives and the impact of contraceptive coverage mandates, 2002.
465. Parents' beliefs about condoms and oral contraceptives: are they medically accurate?
466. Adolescent clinic visits for contraception: support from mothers, male partners and friends.
467. A 3-year double-blind, randomized, controlled study on the influence of two oral contraceptives containing either 20 micrograms or 30 micrograms ethinylestradiol in combination with levonorgestrel on bone mineral density.
468. Abortion as a backup method for contraceptive failure in China.
469. Absence of an effect of injectable and implantable progestin-only contraceptives on subsequent risk of breast cancer.
470. Acceptability of levonorgestrel subdermal implants versus tubal ligation for long-term contraception in a rural population of Zimbabwe.
471. Acceptance of contraceptives among women who had an unsafe abortion in Dar es Salaam.
472. Advanced provision of emergency contraception does not reduce abortion rates.
473. Ambivalence and pregnancy: adolescents' attitudes, contraceptive use and pregnancy.
474. Applying motivational interviewing to contraceptive counseling: ESP for clinicians.
475. Are partners available for post-abortion contraceptive counseling? A pilot study in a Baltimore City clinic.
476. As often as needed: appropriate use of emergency contraceptive pills.
477. The association between depot medroxyprogesterone acetate contraception and bone mineral density in adolescent women.
478. Attitude of German women and gynecologists towards long-cycle treatment with oral contraceptives.
479. Attitudes of married individuals towards oral contraceptives: a qualitative study in Istanbul, Turkey.
480. The availability and use of publicly funded family planning clinics: U.S. trends, 1994-2001.
481. Cervical changes associated with progestagen-only contraceptives: a team approach.
482. Changes in American opinion about family planning.
483. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 micrograms) and gestodene (75 micrograms) [Aspectos clínicos y metabólicos del uso continuo de anticonceptivos con etinilestradiol (30 microgramos) asociado con gestodeno (75 microgramos)]
484. Clinical outcomes of early postplacental insertion of intrauterine contraceptive devices.
485. Ovarian function with the contraceptive vaginal ring or an oral contraceptive: a randomized study.
486. Peri-abortion contraception: a qualitative study of users' experiences.
487. Peripartum contraceptive attitudes and practices.
488. A strategic assessment of abortion and contraception in Romania.
489. Studies on the membrane integrity of human sperm treated with a new injectable male contraceptive.
490. Success with oral contraceptives: a pilot study.
491. Tolerability of levonorgestrel emergency contraception in adolescents.
492. The transdermal contraceptive system.
493. Trends in the use of emergency contraception: an epidemiological study in Barcelona, Spain (1994-2002)
494. Two-year performance of a Nestorone-releasing contraceptive implant: a three-center study of 300 women.
495. Unanswered questions in contraceptive management: what do the experts do?
496. Unmet need for contraception in Kuwait: issues for health care providers.
497. Use of contraception and abortion in Greece: a review.
498. Clinical performance of a levonorgestrel-releasing intrauterine system and oral contraceptives in young nulliparous women: a comparative study.
499. Coil or intrauterine device? Patient preferences for contraceptive terminology.
500. Combined administration of low-dose gossypol acetic acid with desogestrel/mini-dose ethinylestradiol/testosterone undecanoate as an oral contraceptive for men.